Compare LSL Pharma Group, Inc. with Similar Stocks
Dashboard
1
The company is Net-Debt Free
- Poor long term growth as Net Sales has grown by an annual rate of 77.00% over the last 5 years
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 6.95% signifying low profitability per unit of shareholders funds
2
Risky -
3
Consistent Underperformance against the benchmark over the last 3 years
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-22.0%
0%
-22.0%
6 Months
4.0%
0%
4.0%
1 Year
-2.5%
0%
-2.5%
2 Years
-7.14%
0%
-7.14%
3 Years
-29.09%
0%
-29.09%
4 Years
-61.0%
0%
-61.0%
5 Years
-61.0%
0%
-61.0%
LSL Pharma Group, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
77.00%
EBIT Growth (5y)
109.95%
EBIT to Interest (avg)
-0.87
Debt to EBITDA (avg)
8.08
Net Debt to Equity (avg)
0.75
Sales to Capital Employed (avg)
0.38
Tax Ratio
1.43%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.76%
ROE (avg)
6.95%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
2.02
EV to EBIT
53.52
EV to EBITDA
20.62
EV to Capital Employed
1.52
EV to Sales
2.83
PEG Ratio
0.12
Dividend Yield
NA
ROCE (Latest)
2.84%
ROE (Latest)
13.92%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
7.30
5.40
35.19%
Operating Profit (PBDIT) excl Other Income
-2.70
0.80
-437.50%
Interest
0.80
0.60
33.33%
Exceptional Items
0.70
0.00
Consolidate Net Profit
-1.10
4.50
-124.44%
Operating Profit Margin (Excl OI)
-469.80%
52.70%
-52.25%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is 35.19% vs 54.29% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is -124.44% vs 1,000.00% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
28.70
17.70
62.15%
Operating Profit (PBDIT) excl Other Income
0.20
1.90
-89.47%
Interest
2.90
1.90
52.63%
Exceptional Items
-0.10
0.00
Consolidate Net Profit
-2.80
3.30
-184.85%
Operating Profit Margin (Excl OI)
-80.40%
22.90%
-10.33%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 62.15% vs 77.00% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -184.85% vs 138.82% in Dec 2024
About LSL Pharma Group, Inc. 
LSL Pharma Group, Inc.
Gems, Jewellery And Watches
No Details Available.
Company Coordinates 
No Company Details Available






